Live Earnings Conference Call: AbCellera Biologics will host a live Q1 2025 earnings call on May 8, 2025 at 5:00PM ET. Follow this link to get details and listen to AbCellera Biologics' Q1 2025 earnings call when it goes live. Get details. AbCellera Biologics (ABCL) News Today $2.01 -0.02 (-0.99%) Closing price 05/7/2025 04:00 PM EasternExtended Trading$2.06 +0.05 (+2.24%) As of 05/7/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABCL Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period AbCellera Biologics (NASDAQ:ABCL) Trading Down 6.8% - What's Next?AbCellera Biologics (NASDAQ:ABCL) Shares Down 6.8% - Here's What HappenedMay 7 at 4:38 PM | marketbeat.comAbCellera Biologics (ABCL) Projected to Post Quarterly Earnings on ThursdayAbCellera Biologics (NASDAQ:ABCL) will be releasing its Q1 2025 earnings after the market closes on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-abcellera-biologics-inc-stock/)May 3, 2025 | marketbeat.comWalleye Capital LLC Reduces Holdings in AbCellera Biologics Inc. (NASDAQ:ABCL)Walleye Capital LLC lowered its position in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 94.2% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 15,000 shares of the company's stock after selling 241,881 shares during the quarter. WalleyeApril 30, 2025 | marketbeat.comAbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025April 29, 2025 | businesswire.comAbCellera Biologics Inc. (NASDAQ:ABCL) Stock Position Decreased by TD Waterhouse Canada Inc.TD Waterhouse Canada Inc. lowered its holdings in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 55.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 104,594 shares of the company's stock after selling 1April 28, 2025 | marketbeat.comCapital World Investors Takes Position in AbCellera Biologics Inc. (NASDAQ:ABCL)Capital World Investors acquired a new position in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 7,933,613 shares of the company's stock, valued at approximately $23,245,000. Capital WoApril 24, 2025 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Shares Gap Down - Time to Sell?AbCellera Biologics (NASDAQ:ABCL) Shares Gap Down - Here's What HappenedApril 23, 2025 | marketbeat.comIs AbCellera Biologics Inc. (ABCL) the Best Canadian Penny Stock to Invest in Now?April 23, 2025 | msn.comPeak6 LLC Makes New Investment in AbCellera Biologics Inc. (NASDAQ:ABCL)Peak6 LLC acquired a new stake in shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 199,995 shares of the company's stock, valued at approximately $586,000. Peak6 LLC owned approximately 0.07April 23, 2025 | marketbeat.comRenaissance Technologies LLC Sells 459,810 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL)Renaissance Technologies LLC trimmed its holdings in shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 15.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,486,893 shares of the company'sApril 21, 2025 | marketbeat.comBrokers Set Expectations for ABCL Q1 EarningsAbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) - Leerink Partnrs issued their Q1 2026 earnings estimates for AbCellera Biologics in a note issued to investors on Wednesday, April 16th. Leerink Partnrs analyst P. Souda anticipates that the company will post earnings of ($0.16) per share forApril 20, 2025 | marketbeat.comLeerink Partners Remains a Buy on AbCellera Biologics (ABCL)April 19, 2025 | markets.businessinsider.comAbCellera Biologics (NASDAQ:ABCL) Given New $5.00 Price Target at KeyCorpKeyCorp raised their target price on AbCellera Biologics from $4.00 to $5.00 and gave the stock an "overweight" rating in a research report on Wednesday.April 18, 2025 | marketbeat.comAbCellera price target raised to $5 from $4 at KeyBancApril 17, 2025 | markets.businessinsider.comAbCellera: Attractively Priced But A Catalyst Is NeededApril 16, 2025 | seekingalpha.comKeyBanc Remains a Buy on AbCellera Biologics (ABCL)April 16, 2025 | theglobeandmail.comFederated Hermes Inc. Lowers Stock Holdings in AbCellera Biologics Inc. (NASDAQ:ABCL)Federated Hermes Inc. reduced its holdings in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 59.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 916,237 shares of the company's stock after selApril 15, 2025 | marketbeat.com281,795 Shares in AbCellera Biologics Inc. (NASDAQ:ABCL) Purchased by ExodusPoint Capital Management LPExodusPoint Capital Management LP bought a new position in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 281,795 shares of the company's stock, valued atApril 13, 2025 | marketbeat.com1,284,533 Shares in AbCellera Biologics Inc. (NASDAQ:ABCL) Purchased by Norges BankNorges Bank bought a new position in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 1,284,533 shares of the company's stock, valued at approximately $3,764,000. Norges Bank owned aApril 13, 2025 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Hits New 52-Week Low - Should You Sell?AbCellera Biologics (NASDAQ:ABCL) Hits New 12-Month Low - Here's What HappenedApril 9, 2025 | marketbeat.comAbCellera to Participate at Upcoming Investor Conferences in May and JuneApril 8, 2025 | financialpost.comAbCellera Biologics (NASDAQ:ABCL) Shares Up 5.9% - What's Next?AbCellera Biologics (NASDAQ:ABCL) Trading 5.9% Higher - Should You Buy?April 4, 2025 | marketbeat.comDnB Asset Management AS Has $895,000 Holdings in AbCellera Biologics Inc. (NASDAQ:ABCL)DnB Asset Management AS increased its position in shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 424.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 305,579 shares of the company's stApril 4, 2025 | marketbeat.comAbCellera to Report First Quarter 2025 Financial Results on May 8, 2025April 3, 2025 | businesswire.comAbCellera Biologics (NASDAQ:ABCL) Sets New 1-Year Low - Here's WhyAbCellera Biologics (NASDAQ:ABCL) Hits New 52-Week Low - Time to Sell?April 3, 2025 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Stock Price Down 4.1% - Here's What HappenedAbCellera Biologics (NASDAQ:ABCL) Shares Down 4.1% - Time to Sell?March 26, 2025 | marketbeat.comAbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025March 25, 2025 | businesswire.comGuardian Partners Inc. Acquires New Holdings in AbCellera Biologics Inc. (NASDAQ:ABCL)Guardian Partners Inc. acquired a new stake in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,786,414 shares of the company's stock, valuMarch 24, 2025 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Trading Down 3.4% - Here's WhyAbCellera Biologics (NASDAQ:ABCL) Shares Down 3.4% - Time to Sell?March 18, 2025 | marketbeat.comAbCellera: Burning Cash, Searching For 'Blockbusters'March 15, 2025 | seekingalpha.comAbCellera Biologics (NASDAQ:ABCL) Hits New 12-Month Low - Here's WhyAbCellera Biologics (NASDAQ:ABCL) Sets New 52-Week Low - Here's What HappenedMarch 11, 2025 | marketbeat.comWhat is Bloom Burton's Estimate for ABCL FY2025 Earnings?AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) - Research analysts at Bloom Burton dropped their FY2025 earnings per share estimates for AbCellera Biologics in a report issued on Monday, March 3rd. Bloom Burton analyst D. Martin now anticipates that the company will post earnings per shareMarch 7, 2025 | marketbeat.comQ1 Earnings Estimate for ABCL Issued By Bloom BurtonAbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) - Equities researchers at Bloom Burton issued their Q1 2025 EPS estimates for AbCellera Biologics in a research report issued to clients and investors on Monday, March 3rd. Bloom Burton analyst D. Martin expects that the company will earn ($0.1March 6, 2025 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Given "Hold" Rating at BenchmarkBenchmark restated a "hold" rating on shares of AbCellera Biologics in a report on Monday.March 3, 2025 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Shares Gap Down After Analyst DowngradeAbCellera Biologics (NASDAQ:ABCL) Shares Gap Down Following Analyst DowngradeMarch 1, 2025 | marketbeat.comStifel Nicolaus Issues Pessimistic Forecast for AbCellera Biologics (NASDAQ:ABCL) Stock PriceStifel Nicolaus dropped their target price on AbCellera Biologics from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Friday.March 1, 2025 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Reaches New 52-Week Low on Analyst DowngradeAbCellera Biologics (NASDAQ:ABCL) Reaches New 1-Year Low Following Analyst DowngradeMarch 1, 2025 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPSAbCellera Biologics (NASDAQ:ABCL - Get Free Report) posted its earnings results on Thursday. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.04. AbCellera Biologics had a negative net margin of 533.32% and a negative return on equity of 15.73%.February 28, 2025 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Posts Earnings Results, Beats Expectations By $0.04 EPSAbCellera Biologics (NASDAQ:ABCL - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.04. AbCellera Biologics had a negative return on equity of 15.73% and a negative net margin of 533.32%.February 28, 2025 | marketbeat.comAbCellera price target lowered to $10 from $12 at StifelFebruary 28, 2025 | markets.businessinsider.comAbCellera Biologics (ABCL) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | msn.comAbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | seekingalpha.comAbCellera files automatic mixed securities shelfFebruary 27, 2025 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on AbCellera Biologics (ABCL)February 27, 2025 | markets.businessinsider.comAbCellera Reports Full Year 2024 Business ResultsFebruary 27, 2025 | businesswire.comWhat To Expect From AbCellera Biologics Inc (ABCL) Q4 2024 EarningsFebruary 26, 2025 | finance.yahoo.comAbCellera Biologics (ABCL) Projected to Post Earnings on ThursdayAbCellera Biologics (NASDAQ:ABCL) will be releasing earnings after the market closes on Thursday, February 27. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=659273)February 25, 2025 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Stock Price Down 8.5% - Here's What HappenedAbCellera Biologics (NASDAQ:ABCL) Stock Price Down 8.5% - Here's WhyFebruary 21, 2025 | marketbeat.comAbCellera Biologics (ABCL) to Release Quarterly Earnings on ThursdayAbCellera Biologics (NASDAQ:ABCL) will be releasing earnings after the market closes on Thursday, February 27. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=659273)February 20, 2025 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Shares Gap Up - Here's WhyAbCellera Biologics (NASDAQ:ABCL) Shares Gap Up - Time to Buy?February 19, 2025 | marketbeat.com Get AbCellera Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter. Email Address ABCL Media Mentions By Week ABCL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABCL News Sentiment▼0.710.64▲Average Medical News Sentiment ABCL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABCL Articles This Week▼23▲ABCL Articles Average Week Get AbCellera Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Immunovant News Today Metsera News Today ACADIA Pharmaceuticals News Today Apellis Pharmaceuticals News Today Alvotech News Today Amneal Pharmaceuticals News Today Denali Therapeutics News Today Biohaven News Today Organon & Co. News Today NewAmsterdam Pharma News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABCL) was last updated on 5/8/2025 by MarketBeat.com Staff From Our PartnersTrump to redistribute trillions of dollars Seeing how the media and other analysts are covering Trump’s actions – it’s laughable. At least it would be la...Porter & Company | Sponsored270x more lucrative than NVIDIA???270x more lucrative than NVIDIA??? If you've missed out on NVIDIA's recent 1,600% run... Don't worry. ...Behind the Markets | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredVanishing BenefitsWhat would you do if your next Social Security check simply never arrived? If you called and the line was d...Investors Alley | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredElon’s Been UpgradedThe New Elon Musk is officially stepping back from his day-to-day duties with DOGE. At least, that's the s...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbCellera Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ABCL Stock Free ABCL Stock Alerts